Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study

BACKGROUND: Identifying the patients who may benefit the most from immune checkpoints inhibitors remains a great challenge for clinicians. Here we investigate on blood serum amyloid A (SAA) as biomarker of response to upfront pembrolizumab in patients with advanced non-small-cell lung cancer (NSCLC)...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancer Immunol Immunother
Главные авторы: Di Noia, Vincenzo, D’Argento, Ettore, Pilotto, Sara, Vita, Emanuele, Ferrara, Miriam Grazia, Damiano, Paola, Ribelli, Marta, Cannella, Antonella, Virtuoso, Antonella, Fattorossi, Andrea, Ceresoli, Giovanni Luca, Milella, Michele, Beretta, Giordano Domenico, Tortora, Giampaolo, Bria, Emilio
Формат: Artigo
Язык:Inglês
Опубликовано: Springer Berlin Heidelberg 2020
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8139913/
https://ncbi.nlm.nih.gov/pubmed/33231726
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-020-02788-1
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы